Patents by Inventor Chang Kwon

Chang Kwon has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190321485
    Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Application
    Filed: July 9, 2019
    Publication date: October 24, 2019
    Inventors: SUNG YOUB JUNG, DAE JIN KIM, SUNG HEE PARK, YOUNG EUN WOO, IN YOUNG CHOI, SE CHANG KWON
  • Patent number: 10442848
    Abstract: The present invention relates to a novel peptide showing more excellent activities on a glucagon like peptide-1 receptor and a glucagon receptor than native oxyntomodulin, and a composition for the prevention or treatment of obesity comprising the peptide as an active ingredient. Unlike native oxyntomodulin, the novel peptide of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis with reduced side-effects, and also shows excellent receptor-activating effects. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 15, 2019
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Sung Youb Jung, Myung Hyun Jang, Ling Ai Shen, Young Kyung Park, Young Jin Park, Se Chang Kwon
  • Patent number: 10441665
    Abstract: Provided are a liquid formulation of long-acting insulinotropic peptide conjugate, containing a pharmaceutically effective amount of long-acting insulinotropic peptide conjugate consisting of a physiologically active peptide, insulinotropic peptide, and an immunoglobulin Fc region; and an albumin-free stabilizer, wherein the stabilizer comprises a buffer, a sugar alcohol, and a non-ionic surfactant, and a method for preparing the formulation. For the purpose of preventing microbial contamination, a preservative may be added. The liquid formulation of the present invention is free of human serum albumin and other potentially hazardous factors to body, having no risk of viral contamination, and thus can provide excellent storage stability for insulinotropic peptide conjugates at high concentration.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: October 15, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Sung Hee Hong, Dae Jin Kim, Sung Min Bae, Se Chang Kwon
  • Patent number: 10435459
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
    Type: Grant
    Filed: February 5, 2019
    Date of Patent: October 8, 2019
    Assignee: Hanmi Pharm. Co., Ltd.
    Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
  • Publication number: 20190269779
    Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
    Type: Application
    Filed: March 18, 2019
    Publication date: September 5, 2019
    Inventors: HYUN UK KIM, HYUNG KYU LIM, MYUNG HYUN JANG, SANG YUN KIM, SUNG MIN BAE, SE CHANG KWON
  • Publication number: 20190269787
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Application
    Filed: March 12, 2019
    Publication date: September 5, 2019
    Applicant: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10400020
    Abstract: The present invention relates to a long-acting conjugate of a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: September 3, 2019
    Assignee: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10400409
    Abstract: An oil-collecting apparatus includes: a body including an inlet through which a liquid is introduced, a first outlet through which purified water generated from the liquid introduced through the inlet is discharged, and a second outlet through which materials collected from the liquid are discharged; and a filter arranged at the first outlet of the body and generating the purified water by collecting the materials included in the liquid by allowing the liquid introduced through the inlet to pass therethrough.
    Type: Grant
    Filed: December 27, 2017
    Date of Patent: September 3, 2019
    Assignee: Korea Institute of Science and Technology
    Inventors: Heon Ju Lee, Myoung-Woon Moon, O Chang Kwon, Do Hyun Kim, Tae Jun Ko, Ho-Young Kim, Hyungmin Park, Kyu Hwan Oh
  • Publication number: 20190255467
    Abstract: The present disclosure relates to a rotating type foreign substance collection equipment, and according to an embodiment of the present disclosure, there is an effect in separating and collecting foreign substances such as oil from foreign substance-fluid mixtures at high speeds by the separation membrane that traps foreign substances such as oil that float in water while allowing sea water or river water to pass through and be discharged.
    Type: Application
    Filed: September 10, 2018
    Publication date: August 22, 2019
    Inventors: Myoung-Woon MOON, Kwang Ryeol LEE, Seohyun CHO, Young A LEE, O Chang KWON
  • Publication number: 20190257050
    Abstract: The present disclosure relates to a fence having a hydrophilic material, and according to an embodiment of the present disclosure, there is an effect in collecting oil or hazardous & noxious substances quickly and efficiently while minimizing the pressure caused by water, by forming the fence from a material that allows water to penetrate while disallowing oil to penetrate. Additionally, there is an effect in preventing oil spill phenomena caused by damage or unbalance of the fence by reducing the water pressure applied to the fence due to water penetration even when a strong water pressure acts on the fence, for example, strong tidal currents occur and the fence is towed at high speeds to collect oil.
    Type: Application
    Filed: September 10, 2018
    Publication date: August 22, 2019
    Inventors: Myoung-Woon MOON, Kwang Ryeol LEE, O Chang KWON, Seohyun CHO, Young A LEE
  • Patent number: 10370426
    Abstract: The present invention relates to a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Grant
    Filed: June 29, 2018
    Date of Patent: August 6, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Euh Lim Oh, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10363320
    Abstract: The present invention relates to a conjugate comprising oxyntomodulin, an immunoglobulin Fc region, and non-peptidyl polymer wherein the conjugate being obtainable by covalently linking oxyntomodulin to immunoglobulin Fc region via non-peptidyl polymer, and a pharmaceutical composition for the prevention or treatment of obesity comprising the conjugates. The conjugate comprising oxyntomodulin and the immunoglobulin Fc of the present invention reduces food intake, suppresses gastric emptying, and facilitates lipolysis without side-effects, unlike native oxyntomodulin, and also shows excellent receptor-activating effects and long-term sustainability, compared to native oxyntomodulin. Thus, it can be widely used in the treatment of obesity with safety and efficacy.
    Type: Grant
    Filed: June 28, 2017
    Date of Patent: July 30, 2019
    Assignee: Hanmi Science Co., Ltd.
    Inventors: Sung Youb Jung, Dae Jin Kim, Sung Hee Park, Young Eun Woo, In Young Choi, Se Chang Kwon
  • Publication number: 20190218269
    Abstract: A a triple agonist having activities to all of glucagon, GLP-1, and GIP receptors is disclosed. Uses of the triple agonist are disclosed.
    Type: Application
    Filed: March 29, 2019
    Publication date: July 18, 2019
    Applicant: HANMI PHARM. CO., LTD
    Inventors: Euh Lim OH, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Publication number: 20190169271
    Abstract: The present invention relates to a pharmaceutical composition for the prevention or treatment of non-alcoholic fatty liver disease including a long-acting GLP-1/glucagon receptor dual agonist, and a method for preventing or treatment of non-alcoholic fatty liver disease including administering the composition. The composition of the present invention either has no side effect of weight gain or reduces the side effect of weight gain, which is a side-effect of conventional therapeutic agents for non-alcoholic fatty liver disease, and reduces the amount of administrations of a long-acting GLP-1/glucagon receptor dual agonist, thus greatly improving patient's convenience. In addition, the long-acting GLP-1/glucagon receptor dual agonist of the present invention improves in vivo sustainability and stability.
    Type: Application
    Filed: February 5, 2019
    Publication date: June 6, 2019
    Inventors: Sang Youn Hwang, Jin Young Kim, Seung Su Kim, In Young Choi, Sung Youb Jung, Se Chang Kwon
  • Publication number: 20190161368
    Abstract: Provided are spilled oil collecting apparatus and method. The spilled oil collecting apparatus includes: a filter portion made of a porous substrate with hydrophilicity and having an open upper portion so as to collect oil; a frame portion provided at an upper end of the filter portion to support the filter portion; and a handle portion connected to the frame portion. According to the spilled oil collecting apparatus and method, it is possible to collect, separate, and store simultaneously spilled oil spilled from rivers or seas by using a porous substrate having hydrophilicity and optimize immediate collection of spilled oil by maximizing oil collection efficiency and minimizing labour force in an oil collecting process.
    Type: Application
    Filed: November 8, 2018
    Publication date: May 30, 2019
    Inventors: Myoung Woon MOON, Young A LEE, Tae Jun KO, Min Sung KIM, O Chang KWON, Kyu Hwan OH
  • Publication number: 20190153060
    Abstract: A long-acting conjugate of a triple agonist which has activities to all of glucagon, GLP-1, and GIP receptors and uses thereof.
    Type: Application
    Filed: January 31, 2019
    Publication date: May 23, 2019
    Applicant: HANMI PHARM. CO., LTD.
    Inventors: Euh Lim OH, Jong Suk Lee, Young Jin Park, Chang Ki Lim, Sung Youb Jung, Se Chang Kwon
  • Patent number: 10279041
    Abstract: The present invention relates to an albumin-free liquid formulation comprising a long-lasting oxyntomodulin conjugate in which an oxyntomodulin peptide comprising a derivative, variant, precursor or fragment of oxyntomodulin is linked to an immunoglobulin Fc region, which can increase the duration of physiological activity of the long-lasting oxyntomodulin conjugate and maintain the in vivo stability thereof for an extended period of time, as compared to native oxyntomodulin, as well as a method for preparing the liquid formulation. The liquid formulation comprises a buffer, a sugar alcohol and a nonionic surfactant and does not contain a human serum albumin and factors that are potentially harmful to the human body, and thus is not susceptible to viral infection.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: May 7, 2019
    Assignee: Hanmi Pharm Co. Ltd.
    Inventors: Hyun Uk Kim, Hyung Kyu Lim, Myung Hyun Jang, Sang Yun Kim, Sung Min Bae, Se Chang Kwon
  • Patent number: 10272159
    Abstract: Disclosed is an IgG Fc fragment useful as a drug carrier. A recombinant vector expressing the IgG Fc fragment, a transformant transformed with the recombinant vector, and a method of preparing an IgG Fc fragment are disclosed. When conjugated to a certain drug, the IgG Fc fragment improves the in vivo duration of action of the drug and minimizes the in vivo activity reduction of the drug.
    Type: Grant
    Filed: July 9, 2014
    Date of Patent: April 30, 2019
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Sung Youb Jung, Jin Sun Kim, Geun Hee Yang, Se Chang Kwon, Gwan Sun Lee
  • Patent number: 10251957
    Abstract: The present invention relates to a composition for the prevention or treatment of diabetes comprising a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a therapeutic method for the treatment of diabetes, and more particularly, concurrent administration of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain caused by insulin treatment, and vomiting and nausea caused by insulinotropic peptide treatment, and reduces the required dose of insulin, thereby remarkably improving drug compliance. Moreover, each of the long-acting insulin conjugate and the long-acting insulinotropic peptide conjugate of the present invention is prepared by linking insulin or insulinotropic peptide with an immunoglobulin Fc region via a non-peptidyl linker, thereby showing improved in-vivo duration of efficacy and stability.
    Type: Grant
    Filed: June 1, 2012
    Date of Patent: April 9, 2019
    Assignee: HANMI SCIENCE CO., LTD.
    Inventors: Young Eun Woo, Myung Hyun Jang, Young Jin Park, Young Kyung Park, Chang Ki Lim, Se Chang Kwon
  • Patent number: 10253082
    Abstract: The present invention relates to an insulin analog that has reduced insulin receptor binding affinity for the purpose of increasing the blood half-life of insulin, and long-acting insulin, a conjugate, and a method of preparing long-acting insulin using the same.
    Type: Grant
    Filed: January 20, 2015
    Date of Patent: April 9, 2019
    Assignee: HANMI PHARM. CO., LTD
    Inventors: Sung Youb Jung, Sang Youn Hwang, Euh Lim Oh, Sung Hee Park, Hyun Uk Kim, Chang Ki Lim, Se Chang Kwon